Non Hodgkin Lymphoma

Biogen Inc (NASDAQ: BIIB) has exercised its option to participate in the development and commercialization of mosunetuzumab, a CD20xCD3 T-cell engaging bispecific antibody for B-cell non-Hodgkin's lymphoma (NHL), including follicular lymphoma (FL) and diffuse large B-cell...

Adicet Bio Inc (NASDAQ: ACET) has announced positive interim data from its dose-escalation Phase 1 study evaluating ADI-001 for B-cell Non-Hodgkin's Lymphoma.  Adicet's AD-001 is an off-the-shelf cell therapy developed by engineering a CD20-targeting chimeric antigen...

The European Commission has approved BeiGene Ltd's (NASDAQ: BGNE) BRUKINSA (zanubrutinib) for Waldenström's macroglobulinemia (WM). WM is a type of non-Hodgkin lymphoma. This rare blood cell cancer is characterized by an excess of abnormal white blood cells in the bone...

Affimed NV (NASDAQ: AFMD) has announced interim clinical results from the investigator-initiated Phase 1/2 study evaluating cbNK cells pre-complexed with Affimed's innate cell engager (ICE) AFM13. Eighteen patients with CD30-positive relapsed or refractory Hodgkin and non-...

The FDA has accepted for review Incyte Corporation's (NASDAQ: INCY) marketing application for parsaclisib for relapsed or refractory follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL). Parsaclisib is an investigational novel potent, highly...

Mustang Bio Inc (NASDAQ: MBIO) has been awarded a grant of approximately $2 million from the National Cancer Institute of the National Institutes of Health (NIH).  The two-year award will partially fund the Phase 1 trial to assess the safety, tolerability, and efficacy of MB-...

Novartis AG's (NYSE: NVS) Kymriah (tisagenlecleucel) CAR-T therapy failed to meet its primary endpoint of event-free survival in a Phase 3 study in aggressive B-cell non-Hodgkin lymphoma (NHL). The BELINDA study included patients after relapse or lack of response to first-line...

Genentech, a member of Roche Holdings AG (OTC: RHHBY), announced that the pivotal Phase 3 POLARIX trial met its primary endpoint in people with previously untreated diffuse large B-cell lymphoma (DLBCL). The trial investigated Polivy (polatuzumab vedotin) in combination with...

Shares of Kite Pharma Inc (NASDAQ: KITE) were trading higher by more than 2 percent early Wednesday morning after the company's management provided an update on an ongoing Phase 1 trial at an industry conference. Kite Pharma's management spoke at the American Association of Cancer Research's annual...